SEARCH:   Advanced

Blood, 3 September 2009, Vol. 114, No. 10, pp. 2068-2076. Prepublished online as a Blood First Edition Paper on May 14, 2009; DOI 10.1182/blood-2009-03-213280. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-03-213280v1 114/10/2068    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Bartel, T. B. Articles by Barlogie, B. PubMed PubMed Citation Articles by Bartel, T. B. Articles by Barlogie, B. Related Collections Free Research Articles Lymphoid Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Twyla B. Bartel1, Jeff Haessler2, Tracy L. Y. Brown1, John D. Shaughnessy, Jr3, Frits van Rhee3, Elias Anaissie3, Terri Alpe1, Edgardo Angtuaco1, Ronald Walker4, Joshua Epstein3, John Crowley2, and Bart Barlogie3 1 Department of Radiology, University of Arkansas for Medical Sciences, Little Rock; 2 Cancer Research and Biostatistics, Seattle, WA; 3 Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock; and 4 Department of Radiology, Vanderbilt University and Tennessee Valley Veteran's Affairs Healthcare System, Nashville F18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a powerful tool to investigate the role of tumor metabolic activity and its suppression by therapy for cancer survival. As part of Total Therapy 3 for newly diagnosed multiple myeloma, metastatic bone survey, magnetic resonance imaging, and FDG-PET scanning were evaluated in 239 untreated patients. All 3 imaging techniques showed correlations with prognostically relevant baseline parameters: the number of focal lesions (FLs), especially when FDG-avid by PET-computed tomography, was positively linked to high levels of β-2-microglobulin, C-reactive protein, and lactate dehydrogenase; among gene expression profiling parameters, high-risk and proliferation-related parameters were positively and low-bone-disease molecular subtype inversely correlated with FL. The presence of more than 3 FDG-avid FLs, related to fundamental features of myeloma biology and genomics, was the leading independent parameter associated with inferior overall and event-free survival. Complete FDG suppression in FL before first transplantation conferred significantly better outcomes and was only opposed by gene expression profiling-defined high-risk status, which together accounted for approximately 50% of survival variability (R2 test). Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A new pet for myeloma Meletios-Athanassios Dimopoulos, Lia A. Moulopoulos, and Evangelos Terpos Blood 2009 114: 2007-2008. [Abstract] [Full Text] [PDF] This article has been cited by other articles: M.-A. Dimopoulos, L. A. Moulopoulos, and E. Terpos A new pet for myeloma Blood, September 3, 2009; 114(10): 2007 - 2008. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020